

Unique Identifier	Status	Course Title	Record Date	Expiration Date	Renewal Date
23R01789		Mayo Clinic Talks Podcast Series - Season 3	4/6/2023	4/6/2026	
23R01789		Mayo Clinic Talks Podcast Series - Season 3	5/22/2023	5/22/2023	

Podcast Release Date	Ethos Publish Date	Ethos End Date	Faculty	Primary Appointment
12/12/2023	12/15/2023	2/1/2026	Darryl S. Chutka, M.D.; Mohit Chauhan, M.B.B.S.	Gastroenterology
12/19/2023	11/17/2023	12/22/2023	Darryl S. Chutka, M.D., Ericka E. Tung, M.D., M.P.H.	Community and Internal Medicine

Title	Duration (hrs:min:sec)	Learner Assessment Time	Updated Run time with assessment	Credit Count
Functional bowel disorders: Identification and Treatment Updates	0:26:07	0:03:00	0:29:07	0.25
Approach to the Older Adult With New Cognitive Symptoms	0:24:06	0:03:00	0:27:06	0.25

Description

Functional bowel disorders are very common, most often tend to affect those under the age of 50 and can cause symptoms ranging from a mild inconvenience to severe debilitation. Symptoms can vary significantly from patient to patient and the treatment varies with the predominant symptoms. While the exact cause isn't known, there are a few interesting associations with other health conditions. In this podcast, we'll discuss functional bowel disorders with gastroenterologist, Tisha N. Lunsford, M.D., from the Mayo Clinic. We'll review common symptoms, the recommended evaluation, and the available management options for functional bowel disorders.

If we see older patients, we commonly see Alzheimer's Disease and other dementias in our practice. At times, the presenting symptoms can be quite subtle and it's not uncommon for the diagnosis to take several years to establish. Very often, any early symptoms which are noticed are attributed to the aging process. Although we don't have very effective options for treating dementia, it's still important to diagnose the condition as early as possible. In this podcast, we'll be discussing "Assessing the Older Patient with New Cognitive Symptoms." We'll review the usefulness of a mental status exam, recommended lab tests, whether a brain imaging study is indicated and more with our guest, Ericka E. Tung, M.D., M.P.H., an internist, and geriatrician from the Division of Community Internal Medicine at the Mayo Clinic.

Assessment Question	Disclosure Saved
<p>Which of the following statements regarding functional bowel disorders is correct?</p> <ol style="list-style-type: none"> 1. Functional bowel disorders involve the lower GI tract and functional dyspepsia is not included in the disorder. 2. There is no genetic component in functional bowel disorders. 3. Patients who have a history of functional bowel disorder are at increased risk of developing inflammatory bowel disease. 4. Individuals who have had a bacterial infection of the GI tract can develop functional bowel disorder. 5. Patients with functional bowel disorders do not have an increased likelihood of food intolerances. 	Yes
<p>Which of the following statements regarding the patient with new cognitive symptoms is correct?</p> <ol style="list-style-type: none"> 1. The physical exam is the most important component of the assessment of a patient with new cognitive concerns. 2. Once a diagnosis of dementia has been established in a patient, it is not important to identify the specific type of dementia present. 3. The purpose in performing a head imaging study in patients with suspected dementia is to confirm the diagnosis. 4. New treatment options have been FDA-approved which result in improved in cognitive function in patients with Alzheimer's Disease. 5. Aducanumab and lecanemab are monoclonal antibodies which can decrease the amount of amyloid present in the CNS in patients with Alzheimer's Disease. <p>Correct answer: #5</p>	Yes

Relevant financial relationship(s) with industry:	No relevant financial relationship(s) with industry:
Darryl S. Chutka, M.D. - Stock/Shareholder: Exact Sciences Corp	Tisha N. Lunsford, M.D.
Darryl S. Chutka, M.D. - Stock/Shareholder: Exact Sciences Corp;	Ericka E. Tung, M.D., M.P.H.

References to off-label and/or investigational usage(s) of pharmaceuticals or instruments in their presentation:					
None					
None					